

**Product Name:** Ritonavir

**Catalog No.:** 5856


**Batch No.:** 1

CAS Number: 155213-67-5

IUPAC Name: 5-Thiazolylmethyl (3S,4S,6S,9S)-4-hydroxy-12-methyl-9-(1-methylethyl)-13-[2-(1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis(phenylmethyl)-2,7,10,12-tetraazatridecanoate

**1. PHYSICAL AND CHEMICAL PROPERTIES**

**Batch Molecular Formula:** C<sub>37</sub>H<sub>48</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub>  
**Batch Molecular Weight:** 720.94  
**Physical Appearance:** White solid  
**Solubility:** DMSO to 20 mM with gentle warming  
 ethanol to 10 mM  
**Storage:** Store at -20°C  
**Batch Molecular Structure:**



**2. ANALYTICAL DATA**

**HPLC:** Shows 99.6% purity  
**<sup>1</sup>H NMR:** Consistent with structure  
**Mass Spectrum:** Consistent with structure

**Microanalysis:**

	Carbon	Hydrogen	Nitrogen
Theoretical	61.64	6.71	11.66
Found	62	6.76	11.54

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

**Product Name:** Ritonavir

**Catalog No.:** 5856

**Batch No.:** 1

CAS Number: 155213-67-5

IUPAC Name: 5-Thiazolylmethyl (3S,4S,6S,9S)-4-hydroxy-12-methyl-9-(1-methylethyl)-13-[2-(1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis(phenylmethyl)-2,7,10,12-tetraazatridecanoate

**Description:**

Ritonavir is a HIV-1 and HIV-2 protease inhibitor (EC<sub>50</sub> values are 0.022-0.13 and 0.16 μM, respectively). Blocks the metabolism of protease inhibitors by liver enzyme cytochrome P450-3A4 (CYP3A4). Orally bioavailable. When used in combination with lopinavir, improves outcome in an animal model of MERS-CoV infection.

**Physical and Chemical Properties:**


Batch Molecular Formula: C<sub>37</sub>H<sub>48</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub>

Batch Molecular Weight: 720.94

Physical Appearance: White solid

**Minimum Purity:** ≥98%

**Batch Molecular Structure:**



**References:**

**Chan et al** (2015) Treatment with Lopinavir/Ritonavir or Interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. *J.Infect.Dis.* **12** 1904. PMID: 26198719.

**Zeldin et al** (2004) Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. *J.Antimicrob.Chemother.* **53** 4. PMID: 14657084.

**Kempf et al** (1998) Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. *J.Med.Chem.* **41** 602. PMID: 9484509.

**Storage:** Store at -20°C

**Solubility & Usage Info:**

DMSO to 20 mM with gentle warming  
ethanol to 10 mM

**Stability and Solubility Advice:**

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

**SOLIDS:** Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

**SOLUTIONS:** We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

**bio-techne.com**

info@bio-techne.com

techsupport@bio-techne.com

**North America**

Tel: (800) 343 7475

**China**

info.cn@bio-techne.com

Tel: +86 (21) 52380373

**Europe Middle East Africa**

Tel: +44 (0)1235 529449

**Rest of World**

www.tocris.com/distributors

Tel:+1 612 379 2956